356 related articles for article (PubMed ID: 27131082)
1. Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.
Muldermans JL; Romak LB; Kwon ED; Park SS; Olivier KR
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):696-702. PubMed ID: 27131082
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
3. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.
Decaestecker K; De Meerleer G; Lambert B; Delrue L; Fonteyne V; Claeys T; De Vos F; Huysse W; Hautekiet A; Maes G; Ost P
Radiat Oncol; 2014 Jun; 9():135. PubMed ID: 24920079
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
5. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
Ost P; Jereczek-Fossa BA; Van As N; Zilli T; Tree A; Henderson D; Orecchia R; Casamassima F; Surgo A; Miralbell R; De Meerleer G
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e115-20. PubMed ID: 27133946
[TBL] [Abstract][Full Text] [Related]
6. Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience.
Ponti E; Ingrosso G; Carosi A; Di Murro L; Lancia A; Pietrasanta F; Santoni R
Clin Genitourin Cancer; 2015 Aug; 13(4):e279-e284. PubMed ID: 25604915
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non-Small Cell Lung Cancer.
Parks J; Kloecker G; Woo S; Dunlap NE
Am J Clin Oncol; 2016 Apr; 39(2):147-53. PubMed ID: 24457534
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
Rogowski P; Trapp C; von Bestenbostel R; Schmidt-Hegemann NS; Shi R; Ilhan H; Kretschmer A; Stief C; Ganswindt U; Belka C; Li M
Radiat Oncol; 2021 Jun; 16(1):125. PubMed ID: 34193194
[TBL] [Abstract][Full Text] [Related]
9. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer.
Jereczek-Fossa BA; Piperno G; Ronchi S; Catalano G; Fodor C; Cambria R; Fossati Ing P; Gherardi F; Alterio D; Zerini D; Garibaldi C; Baroni G; De Cobelli O; Orecchia R
Am J Clin Oncol; 2014 Jun; 37(3):227-33. PubMed ID: 22992626
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
12. Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer.
Zelefsky MJ; Yamada Y; Greco C; Lis E; Schöder H; Lobaugh S; Zhang Z; Braunstein S; Bilsky MH; Powell SN; Kolesnick R; Fuks Z
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(3):672-679. PubMed ID: 33422612
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience.
Cuccia F; Tamburo M; Piras A; Mortellaro G; Iudica A; Daidone A; Federico M; Zagardo V; Ferini G; Marletta F; Spatola C; Fazio I; Filosto S; Pergolizzi S; Ferrera G
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629732
[No Abstract] [Full Text] [Related]
14. Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes.
Lewin R; Amit U; Laufer M; Berger R; Dotan Z; Domachevsky L; Davidson T; Portnoy O; Tsvang L; Ben-Ayun M; Weiss I; Symon Z
Radiat Oncol; 2021 Jun; 16(1):114. PubMed ID: 34162398
[TBL] [Abstract][Full Text] [Related]
15. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
[TBL] [Abstract][Full Text] [Related]
16. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.
Jereczek-Fossa BA; Beltramo G; Fariselli L; Fodor C; Santoro L; Vavassori A; Zerini D; Gherardi F; Ascione C; Bossi-Zanetti I; Mauro R; Bregantin A; Bianchi LC; De Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):889-97. PubMed ID: 21277113
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.
Pezzulla D; Macchia G; Cilla S; Buwenge M; Ferro M; Bonome P; Romano C; Zamagni A; Valentini V; Morganti AG; Deodato F
Clin Exp Metastasis; 2021 Dec; 38(6):519-526. PubMed ID: 34651242
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer.
Patel PH; Chaw CL; Tree AC; Sharabiani M; van As NJ
World J Urol; 2019 Dec; 37(12):2615-2621. PubMed ID: 31346760
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate?
Kalash R; Glaser SM; Flickinger JC; Burton S; Heron DE; Gerszten PC; Engh JA; Amankulor NM; Vargo JA
J Neurosurg Spine; 2018 Aug; 29(2):220-225. PubMed ID: 29799334
[TBL] [Abstract][Full Text] [Related]
20. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E
Christ SM; Alongi F; Ricardi U; Scorsetti M; Livi L; Balermpas P; Lievens Y; Braam P; Jereczek-Fossa BA; Stellamans K; Ratosa I; Widder J; Peulen H; Dirix P; Bral S; Ramella S; Hemmatazad H; Khanfir K; Geets X; Jeene P; Zilli T; Fournier B; Ivaldi GB; Clementel E; Fortpied C; Oppong FB; Ost P; Guckenberger M
Radiother Oncol; 2024 Jun; 195():110235. PubMed ID: 38508239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
